Results 81 to 90 of about 278,336 (309)
SOX2 Inhibits Cuproptosis to Affect Cisplatin Resistance in Non-Small Cell Lung Cancer by Activating the Wnt/ATP7B Signaling Pathway. [PDF]
Kaohsiung J Med SciABSTRACT Cisplatin (CDDP) resistance constitutes the principal clinical challenge in the treatment of advanced non‐small cell lung cancers (NSCLC). Disturbances in copper metabolism are closely linked with tumor drug resistance. SOX2, a pivotal stemness transcription factor (TF), holds an important role in chemotherapy resistance.
Chen K +5 more
europepmc +2 more sources
Screening and diagnosis of NSCLC
Annals of Oncology, 2004 Lung cancer is the biggest cancer killer in Europe. Non-small-cell lung cancer (NSCLC) accounts for the vast majority ofcases. The annual number of newly diagnosed patients inEurope exceeds 200000, accounting for 20% of all cancerdeaths, and on average 28% of male cancer deaths across thecontinent [1, 2].
Van Meerbeeck, Jan, Tournoy, Kurt
openaire +3 more sources
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports [PDF]
, 2019 Pembrolizumab is an immune checkpoint inhibitor (ICI), currently recommended as the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) showing 50% expression of programmed death-ligand 1 (PD-L1).
Bychkov, Andrey +7 more
core +1 more source
FEBS Open Bio, EarlyView.Glioblastoma cells express calcitonin receptor variants (CT receptor isoforms) that may help them survive stress. Using qPCR, transcript‐specific long‐read nanopore sequencing, immunofluorescence co‐localisation and comparative sequence analysis, this study identifies a novel alternatively spliced CALCR transcript that encodes the CTb receptor isoform ...
Pragya Gupta +7 more
wiley +1 more source
Open Life Sciences, 2016 Lung cancer is the leading cause of cancer-related death, with non-small cell lung cancer (NSCLC) accounting for more than 80% of all lung cancer cases.
Yunxia Zhang, Hongying Dong
doaj +1 more source
Predicting overall survival of NSCLC patients with clinical, radiomics and deep learning features.
This data package contains the information needed to replicate the research titled - 'Predicting overall survival of NSCLC patients with clinical, radiomics and deep learning features'
Kanakarajan, Hemalatha +8 more
core +1 more source
Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
, 2021 Non-small cell lung cancer (NSCLC) is of major concern for society as it is associated with high mortality and is one of the most commonly occurring of all cancers. Due to the number of mutational variants and general heterogeneity of this type of cancer,
Munn, Alan L +4 more
core +1 more source
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
Aging and Cancer, EarlyView.This graphical abstract illustrates the key biological pathways linking aging with cancer development and progression. In the upper left, cumulative exposure to ultraviolet radiation, toxins, and reactive oxygen species (ROS) causes DNA damage and genomic instability, whereas age‐related decline in repair mechanisms, such as ATM/ATR, BER, and NER ...
Anu Singh, Aroonima Misra, Sufian Zaheer
wiley +1 more source
The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma
OncoImmunology, 2018 Despite the opposite roles of Tbet and Foxp3 in the immune system as well as in tumour biology, recent studies have demonstrated the presence of of CD4+ T cells, expressing both, Tbet and Foxp3.
Katerina Kachler +4 more
doaj +1 more source
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
, 2017 Alessia E Russo,1 Domenico Priolo,1 Giovanna Antonelli,1 Massimo Libra,2 James A McCubrey,3 Francesco Ferraù1 1Medical Oncology Department, San Vincenzo Hospital, Taormina (Messina), Italy; 2Laboratory of Translational Oncology & Functional ...
Antonelli G +17 more
core +1 more source